Oral Ritlecitinib and Brepocitinib for Moderate-to-Severe Ulcerative Colitis: Results From a Randomized, Phase 2b Study - Sandborn, WJ; Danese, S; Leszczyszyn, J (Clin Gastroenterol Hepatol, 2023)